Anthracycline chemotherapeutics, such as doxorubicin, are used widely in the treatment of numerous malignancies. The primary dose-limiting adverse effect of anthracyclines is cardiotoxicity that often presents as heart failure due to dilated cardiomyopathy years after anthracycline exposure. Recent data from animal studies indicate that anthracyclines cause cardiac atrophy. The timing of onset and underlying mechanisms are not well defined, and the relevance of these findings to human disease is unclear.
T
he anthracycline antibiotic doxorubicin is a widely used and highly effective component of adjuvant chemotherapy for breast cancer and curative regimens for lymphomas, leukemias, and soft tissue sarcomas. The primary dose-limiting adverse effect of doxorubicin is cardiotoxicity. Anthracycline-induced cardiomyopathy has become less frequent with contemporary dosing regimens and formulations but continues to be a meaningful source of morbidity and mortality. 1 Cardiotoxicity related to doxorubicin most commonly is detected years after therapeutic exposure and widely is considered to result from chronic maladaptive changes and remodeling. Chronic anthracycline cardiotoxicity typically manifests as dilated cardiomyopathy, with eccentric ventricular hypertrophy and increased cardiac mass, often associated with the clinical syndrome of heart failure. 2 Acute and subacute cardiotoxic response to doxorubicin exposure also occurs. Acute doxorubicin cardiotoxicity is considered a rare clinical event, though numerous recent studies indicate that it is more common than previously thought (11%-21%) 3, 4 and predicts poor outcomes. 5 The pathogenesis of acute doxorubicin cardiotoxicity may be distinct from chronic cardiomyopathy, 6 though the prevailing paradigm considers oxidative stress the central mechanism of injury, associated with mitochondrial dysfunction and cardiomyocyte death. 7, 8 Acute alterations in cardiac structure have not been studied carefully.
The perceived differences between acute and chronic doxorubicin cardiotoxicity not only have implications on clinical management and prognosis but also affect our understanding of experimental models of human disease. Acute doxorubicin exposure is a commonly used, and widely criticized, mouse model of anthracycline cardiotoxicity. Critics contend that the model relies on high doses of doxorubicin, and hence may not accurately model a clinically relevant human condition. 9 The present study sought to clarify the early effects of anthracyclines on cardiac muscle mass in mice and humans.
Here, we show that doxorubicin causes dose-dependent cardiac atrophy in mice, beginning at relatively low dose exposure. Mice lacking MuRF1 (muscle ring finger-1), a striated muscle-specific ubiquitin ligase that has been implicated as a mediator of cardiac atrophy in other mouse models, 10 are resistant to doxorubicininduced cardiac atrophy and contractile dysfunction. Analysis of the DETECT-1 cardiac magnetic resonance imaging (CMR) cohort revealed that cancer patients treated with contemporary anthracycline regimens also undergo cardiac atrophy within 1 month of exposure.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. Mice were 8-to 12-week-old male (or female, where specified) C57Bl6J for dose-response experiments. MuRF1 −/− mice, congenic on a C57Bl6J background, 11 were compared with MuRF1 12 Echocardiograms were performed on awake, loosely restrained mice. The echocardiogram reader was blind to treatment condition. Mice were sacrificed by cervical dislocation after an overdose of isoflurane, and heart tissue was either perfused and fixed (immunohistochemistry) or immediately removed, flash frozen, and processed for quantitative real-time polymerase chain reaction, ATP assay, and immunoblotting. Hearts were fixed and sectioned according to standard procedures. Slides were stained with wheat germ agglutinin Alexa Fluor 488 conjugate and counterstained with 4',6-diamidino-2-phenylindole to visualize cardiomyocyte cross-sectional area.
The DETECT-1 cohort study was approved by the Wake Forest University School of Medicine Institutional Review Board and supported by the National Cancer Institute (R33CA12196). 13 All subjects provided informed and witnessed consent for participation. Longitudinal change in left ventricular (LV) mass was assessed in 70 anthracycline-treated patients who were imaged by CMR a maximum of 4× (at baseline, 1 month, 3 months, and 6 months).
For CMR data, the rate of change in LV mass was analyzed by constructing a linear mixed model with random intercepts and time effects and statistical analyses were performed using SAS 9.4 (SAS Institute; Cary, NC). All other comparisons were made using t test (groups of 2), 1-way ANOVA (groups of 3) with Tukey post hoc analysis, or linear regression (GraphPad
WHAT IS NEW?
• The ubiquitin ligase, MuRF1 (muscle ring finger-1), is upregulated in the hearts of mice treated with doxorubicin.
• Mice lacking MuRF1 are resistant to doxorubicininduced cardiac atrophy.
• Human cardiac mass as measured by magnetic resonance imaging decreases within 1 month of initiating anthracycline therapy.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Cardiac atrophy occurs soon after anthracycline exposure in humans and is associated with worse outcomes. Earlier surveillance with cardiac magnetic resonance imaging could identify actionable cardiotoxicity.
• Therapeutic inhibition of MuRF1 might blunt cardiac atrophy and mitigate anthracycline-induced cardiotoxicity.
Prism; San Diego, CA). Results are presented as mean±SEM, except as specified.
Complete experimental details are available in Methods in the Data Supplement.
RESULTS

Doxorubicin Induces a Dose-Related Decrease in Heart Weight in Wild-Type Mice
To test the effect of doxorubicin on cardiac structure and function, we administered intraperitoneal vehicle or escalating doses of doxorubicin (1, 2, 5, 10, 15, 20 mg/kg one time) to 8-to 12-week-old male wild-type C57B6J mice. We detected a statistically significant decrease in body weight, as compared to vehicle-treated animals, only at the 20 mg/kg dose ( Table 1 ). The average heart weight of mice treated with doxorubicin 20 mg/kg (n=9) was 89±3 mg, 20% lower than the average heart weight of vehicle-treated mice (111±3 mg, n=26). Linear regression analysis indicated that heart weight indexed to body weight decreased in a dose-dependent fashion after doxorubicin administration (P<0.0001; Y=−0.0052×X+0.50; R 2 =0.64), suggesting that cardiac atrophy occurs out of proportion to cachexia or other systemic effects ( Figure 1A ). The decrease in indexed heart weight achieved statistical significance at 10 mg/kg and all higher doses. The relationship between indexed heart weight and Log2-doxorubicin dose was even closer (P=0.007, R 2 =0.87; Figure I in the Data Supplement). Consistent with these findings, heart weight indexed to tibia length (which should be unaffected by systemic illness) was 21% lower in mice treated with doxorubicin 20 mg/kg compared with vehicle-treated mice ( Figure 1B) . In light of a recent report that female mice are relatively resistant to doxorubicin cardiotoxicity, 14 we treated 8-to 12-weekold female C57B6J mice with vehicle or doxorubicin 20 mg/kg and found no significant decrease in heart weight indexed to body weight ( Figure 1C ). All values are mean±SEM, n given in parentheses. 
Doxorubicin Decreases Cardiomyocyte Size With Only Modest Induction of Cardiomyocyte Death
Heart weight decreases either because of a decrease in cell volume or number. To evaluate the effect of doxorubicin on cardiomyocyte volume, we analyzed wheat germ agglutinin-stained sections of vehicle and doxorubicin-treated mouse hearts 7 days after treatment with vehicle or doxorubicin 20 mg/kg. Doxorubicin treatment was associated with a 44% decrease (336±29 versus 188±14 µm 2 ) in cardiomyocyte cross-sectional area ( Figure 2A ).
To assess for doxorubicin-induced cell death in vivo, we measured serum troponin-I by ELISA (LifeDiagnostics) at 1, 3, and 7 days after doxorubicin 20 mg/kg administration. We found a small and transient increase in TnI (serum troponin-I) in doxorubicin-treated mice compared with vehicle (0.11 versus 0.08 ng/mL) at day 3, but this mild elevation was undetectable by day 7 ( Figure 2B ). As a positive control for the ELISA, we measured TnI in the serum of mice (n=4) drawn 24 hours after myocardial infarction induced by left anterior descending coronary artery ligation. The average TnI in these mice was 11.1 ng/mL ( Figure 2B )
To evaluate the contribution of apoptosis to doxorubicin-induced cell death, we used terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) and immunoblotted for classical apoptotic markers. TUNEL stains of fixed heart tissue revealed no evidence of apoptosis in either vehicle or doxorubicin-treated mice (data not shown). There was a significant increase in cleaved caspase 3 only at 10 mg/kg and an increase in cleaved PARP (poly ADP ribose polymerase) only at 25 mg/kg ( Figure 2C and Figure II in the Data Supplement). Collectively, these findings suggest that cardiomyocyte atrophy, rather than cell death, is the primary determinant of the subacute decrease in heart weight after doxorubicin exposure.
Doxorubicin Causes a Dose-Dependent Decrease in Contractile Function That Parallels Cardiac Atrophy
High-dose anthracycline administration causes subacute cardiac dysfunction in male mice, though the dose threshold for injury is unclear. We used conscious echocardiography with blinded readers to assess whether cardiac atrophy after escalating doses of doxorubicin is accompanied by functional deficits. Linear regression analysis indicated that doxorubicin induced a doserelated decrease in fractional shortening (P=0.014, Y=−0.332×X+49.3; R 2 =0.73), an echocardiographic indicator of contractile function ( Figure 3A) . The relationship between fractional shortening and Log2-doxorubicin dose was even closer (P=0.005; R 2 =0.88; Figure III in the Data Supplement). Though chronic doxorubicin cardiotoxicity is characterized by dilated cardiomyopathy, we found no subacute change in LV diastolic diameter or volume but a modest increase in LV systolic diameter and volume (day 7: 7.7±1.1 mL versus day 0: 5.1±0.5 mL; Figure 3B ) and a decrease in calculated LV mass (day 7: 70.5±2.4 mg versus day 0: 57.5±3.4 mg; P=0.005; Figure 3C ) consistent with atrophic hypocontractility.
Doxorubicin Induces a Characteristic Molecular Profile of Atrophy, Including MuRF1 Upregulation
We next used quantitative real-time polymerase chain reaction to evaluate the molecular response to escalating doses of doxorubicin, focusing on genes that classically are upregulated during cardiac atrophy. 15 We found dose-related increases in the expression of striated muscle-specific ubiquitin ligase MuRF1 (P=0.003; Y=0.07597×X+0.6219; R 2 =0.91), as well as its upstream regulator, BNIP3 (BCL2 interacting protein-3). 16 Abundance of the ubiquitin ligase atrogin-1 and the neutral protease calpain-1 ( Figure 4A , Figure IV in the Data Supplement) were not predictably affected by doxorubicin, contrary to previous reports. 17, 18 MHC (myosin heavy chain) isoform predominance underwent characteristic atrophic switching, from MHC-α (MYH6) to MHC-β (MYH7), and ANP (atrial natriuretic peptide) was increased ( Figure 4A ). Interestingly, we also identified a significant increase in both MuRF1 and atrogin-1 mRNA expression in the gastrocnemius muscle of mice treated with doxorubicin 20 mg/kg (Figure V in the Data Supplement). MHC-β abundance was unchanged in gastrocnemius from doxorubicin-treated mice, indicative of previously recognized differences in transcriptional regulation of MHC-β in cardiac and skeletal muscle atrophy. 19 Immunoblotting of the hearts of mice treated with vehicle or doxorubicin 25 mg/kg revealed a nearly 4-fold upregulation of MuRF1 (densitometry relative to GAPDH 0.85±0.06 versus 0.24±0.07; P<0.0001), a MuRF1 regulates cardiac atrophy due to dexamethasone and after reversal of transverse aortic constriction. 10 Given that MuRF1 was increased in the setting of doxorubicin-induced cardiac atrophy, we sought to determine whether this upregulation was causal using mice globally lacking MuRF1 (MuRF1 −/− ) on a C57Bl6J background. 11 Male MuRF1 −/− mice and wild-type (MuRF1 +/+ ) littermates underwent conscious echocardiography before intraperitoneal administration of doxorubicin 20 mg/kg or vehicle, then repeat echocardiography before sacrifice on day 7 posttreatment. Body weight decreased in WT mice after doxorubicin (22.6±0.9 to 19.4±0.9 g) but was unchanged in MuRF1 −/− mice (Table 2, Figure 5A ). Raw heart weight ( Figure 5B ) and heart weight indexed to tibia length ( Figure 5C ) were reduced in MuRF1 +/+ but preserved in MuRF1 −/− mice after doxorubicin. Tibia length was identical in MuRF1 −/− and MuRF1 +/+ mice. Contractile function, as measured by ejection fraction, was decreased Figure 5D and 5E, Table 2 ). Collectively, these findings indicate that MuRF1 mediates subacute doxorubicin-induced cardiac atrophy and contractile dysfunction.
Anthracycline Exposure Is Associated With Early Cardiac Atrophy in Humans
Recent reports have drawn attention to the role of cardiac atrophy in chronic anthracycline-induced cardiotoxicity. 20, 21 The early effects of anthracyclines on human cardiac mass have not been published previously. To assess whether humans undergo subacute cardiac atrophy similar to the mice in our study, we queried the DETECT-1 cohort study data. 13 DETECT-1 enrolled consecutive patients undergoing chemotherapy at a single academic cancer center and followed them with CMR at baseline and 1, 3, and 6 months after initiation of chemotherapy. We identified 70 DETECT-1 subjects who received anthracycline-based chemotherapy (Table 3 ) and analyzed the rate of change in LV mass by CMR, constructing a linear mixed model with random intercepts and time effects. We found a statistically significant decrease in cardiac mass that was evident 1 month after initiation of therapy and persisted throughout the entire 6-month follow-up ( Figure 6 ). In this small sample, we did not find significant associations between cardiac mass and other measures of LV performance, though the study was not powered to identify such associations.
DISCUSSION
We undertook these studies to explicate the role of cardiomyocyte atrophy in the early response to doxorubicin exposure. Clinically detected anthracycline-induced cardiotoxicity most commonly manifests as dilated cardiomyopathy with eccentric cardiac hypertrophy, though the potential for anthracyclines to cause late cardiomyocyte atrophy was recognized decades ago in human autopsy studies. 22 These early case series were performed in an era of high-dose anthracycline treatment in subjects with overtly pathological response to therapy, hence may not be entirely relevant to contemporary practice. We used systematic dose escalation assessment of doxorubicin's effect on cardiac mass to expand on published mouse studies of anthracyclinemediated atrophy that used fixed dosing. 23, 24 Our data indicate that indexed heart weight in mice decreases significantly at 10 mg/kg, a dose that allometrically scales to roughly 30 mg/m 2 in humans 25 -within the limits of current dosing regimens. Our analysis of the DETECT-1 cohort demonstrates that subacute human cardiac atrophy occurs with contemporary anthracycline dosing regimens as well, in patients without a clinical diagnosis of cardiomyopathy or heart failure.
The mass of the postnatal heart decreases either because of decreased myocyte volume or myocyte attrition. Others have reported that doxorubicin can cause cardiac atrophy in mice, 24, 26 and here we present evidence that decreased cardiomyocyte cross-sectional area primarily accounts for the dose-dependent decrease in cardiac mass after doxorubicin exposure. The prevailing paradigm considers cardiomyocyte death, through necrosis or apoptosis, to be central to anthracycline-mediated cardiac injury. 27 However, numerous studies indicate that the contribution of cardiomyocyte death to doxorubicin cardiotoxicity has been overstated historically (reviewed in Kankeu et al 28 ), due in part to the supratherapeutic concentrations of doxorubicin used for in vitro experiments. In particular, the contribution of in vivo apoptosis has been contested by compelling recent work demonstrating the limited apoptotic capacity of the adult mouse heart in response to anthracyclines and irradiation. 29 We find little convincing evidence for doxorubicin-induced apoptosis in this study: TUNEL staining was entirely negative, and immunoblotting for cleaved caspase 3 and cleaved PARP each were elevated at single discrepant doses.
Our present studies in mice and multiple recent human studies 30, 31 indicate that the rise in troponin after contemporary anthracycline treatment is modest and transient, well below a threshold that could be reasonably expected to decrease cardiac mass. Cardiac troponins are released into the serum either through loss of cardiomyocyte membrane integrity or through increased turnover of intracellular troponin by the ubiquitin-proteasome system, 32 including ubiquitin ligases, such as MuRF1. Indeed, troponin-I is a direct target of MuRF1. 33 Interestingly, cardiac atrophy due to other causes, including cancer 34 and anorexia, 35 is associated with elevated serum troponin and other biomarkers of cardiac damage. Collectively, these observations suggest that the early decrease in heart weight after anthracycline exposure likely is largely attributable to myofibrillar atrophy, rather than cardiomyocyte loss. Similarly, it seems possible that early declines in cardiac contractile function after doxorubicin result mostly from depletion of cardiomyocyte contractile apparatus and insults to cardiomyocyte metabolism, 7 rather than cell death. Our findings, coupled with these published data, inform our understanding of a commonly used rodent model of heart injury and may be relevant to anthracycline-induced cardiotoxicity in humans.
The central mechanistic finding of our studies is that doxorubicin-induced cardiac atrophy is mediated by MuRF1. MuRF1 is a striated muscle-specific ubiquitin ligase expressed exclusively in skeletal and cardiac muscle. Ubiquitin ligases add ubiquitin to lysine residues in the side chains of proteins as a posttranslational modification. Ubiquitin ligases are found in all eukaryotic cells and ubiquitination regulates the stability and activity of many proteins, targeting defective proteins to the proteasome for degradation. In cardiomyocytes, the ubiquitin-proteasome system regulates sarcomeric protein turnover to maintain normal heart function. 36 Dysregulation of the ubiquitin-proteasome system contributes to the pathobiology of heart failure. 37 Upregulation of MuRF1, along with atrogin-1 and FOXO3a (forkhead box O3a), accompanies disuse atrophy in skeletal muscle, though there is some controversy as to whether MuRF1 is a bona fide mediator 
MuRF1
−/− and littermate MuRF1 +/+ mice were given doxorubicin 20 mg/kg IP and sacrificed after 7 d. A, Body weight before doxorubicin (day 0) and on the day of sacrifice (day 7); (B) heart mass on day 7; (C) heart mass indexed to tibia length on day 7 (inset: tibia length). D, Contractile function (ejection fraction) was measured using (E) conscious echocardiography. #P<0.05 by Student t test. One-way ANOVA followed by an all pairwise multiple comparison procedure (HolmSidak method) compared multiple groups. *P<0.05 vs column 1 and column 2, **P<0.05 vs all other columns, ***P<0.05 vs. column 1. MuRF indicates muscle ring finger- 1. or merely a marker of atrophy. 38, 39 Here, we confirm previous reports that doxorubicin increases MuRF1 mRNA abundance in mouse heart and skeletal muscle in vivo. 40, 41 We extend these findings by showing that doxorubicin administration causes a dose-dependent increase in expression of MuRF1 and molecular markers of atrophy (MHC-β and ANP) that parallels the decrease in heart weight. The hearts of mice globally lacking MuRF1 were protected from atrophy and contractile dysfunction after doxorubicin exposure, suggesting that MuRF1 upregulation indeed participates in anthracycline-mediated cardiac atrophy, rather than merely serving as a molecular marker.
The role of MuRF1 in cardiac atrophy is complex; it serves both as a ubiquitin ligase and a regulator of transcription.
10 MuRF1 specifically degrades numerous canonical myofibrillar proteins, including MHCα, MHC-β, 42 and cardiac troponin-I. 33 MuRF1 also regulates transcription of key cardiomyocyte genes, including cardiac myosin binding protein C. 43 Considered more broadly, the molecular profiling of atrophy is similarly complex. Multiple etiologies of atrophy all lead to transcriptional induction of MHCβ, ANP, and α-skeletal actin (reviewed in Baskin and Taegtmeyer 15 ) collectively referred to as the fetal gene program for its resemblance to prenatal expression patterns. Upregulation of these same genes long has been associated with cardiac hypertrophy-the morphological converse of atrophy-suggesting the possibility that these changes may simply represent a transcriptional response to injury, rather than critical determinants of phenotype. Consistent with this paradigm, we show dose-dependent increases in fetal genes with an inverse relationship to heart size and myocyte cross-sectional area.
Though our findings directly implicate MuRF1 in doxorubicin-induced cardiac atrophy, we cannot exclude contributions from other mediators. Previous studies found that doxorubicin increases abundance of atrogin-1, another critical muscle-specific ubiquitin ligase, via activation of p38-MAP (mitogen-activated protein) kinase in vitro in neonatal rat ventricular myocytes exposed to doxorubicin. 18 We found no upregulation of either atrogin-1 mRNA or protein in our in vivo model of anthracycline cardiotoxicity, though further experiments in genetically altered mice would be required to fully exclude the involvement of atrogin-1 in doxorubicin-induced cardiac atrophy. Similarly, some reports have shown that calpain-1 contributes to anthracyclineinduced cardiotoxicity and skeletal muscle myopathy. 23 However, other reports indicate that calpain abundance and activity are decreased after doxorubicin exposure in vivo and in vitro. 44 We found no clear relationship between doxorubicin dose and calpain-1 expression, though we cannot entirely exclude a role for calpain-1 in anthracycline-induced cardiac atrophy.
It is possible that some of our findings, including the transience of the troponin elevation, result from the use of a single-dose model that may not accurately recapitulate clinical dosing strategies. We also acknowledge the inherent limitations in the use of inbred mouse strains for the prediction of anthracycline toxicity in humans 45 and chose the widely used C57BL/6 strain for our experiments to facilitate reproduction and extension of our results in other research labs. We hope that the inclusion of clinical data from the DETECT-1 cohort will enhance confidence in the relevance of our findings to the pathobiology of human anthracycline cardiotoxicity.
Skeletal sarcopenia related to chemotherapy is an independent risk factor in patients with multiple types of malignancies. 46, 47 The effects of cancer and its treatment on cardiac muscle mass are less well understood. 48 One previous case series using CMR found that decreased cardiac mass was an independent predictor of adverse events in patients diagnosed with chronic anthracycline-induced cardiomyopathy presenting at a median of 88 months after conclusion of treatment. 49 More recently, a study of 76 patients showed that decreased cardiac mass 6 months after anthracycline exposure was associated with worse heart failure symptoms. 21 A separate study of 27 women used CMR to demonstrate a decrease in cardiomyocyte mass, consistent with cardiomyocyte atrophy, 351 to 700 days after anthracycline-containing chemotherapy. 20 Our analysis of the DETECT-1 cohort extends these findings by identifying decreased cardiac mass within 1 month of anthracycline exposure-to our knowledge, the earliest demonstration of anthracycline-induced atrophy in humans. Coupled with the recent report that CMR ejection fraction decreases 3 months after treatment, 50 our findings suggest that anthracyclines routinely have early adverse effects on the human heart at low contemporary doses. Mounting evidence indicates that cardiomyocyte atrophy contributes to this cardiotoxicity. Previous studies have shown that timely institution of neurohormonal antagonists after detection of anthracycline-induced heart injury can protect against the development of chronic anthracycline cardiomyopathy, 51 suggesting that detection of early-onset subclinical doxorubicin cardiotoxicity may be actionable and clinically meaningful. Our findings indicate that cardiomyocyte atrophy is central to the pathogenesis of acute and subacute anthracycline-induced cardiotoxicity and suggest that therapies directed at preventing or reversing cardiac atrophy, including MuRF1 antagonists, 52 might preserve the cardiac function of cancer patients receiving anthracyclines. 
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